Ratings Grifols, S.A.

Equities

Real-time Estimate Tradegate Other stock markets 03:10:23 20/09/2024 pm IST			5-day change	1st Jan Change
10.04 ^EUR	-0.35%		-1.95%	-35.04%

09:40am	Grifols minority shareholders team up to ask for a board seat	RE
07:53am	Minority Investors' Group Seeks Representation on Grifols Board	MT

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company has a good ESG score relative to its sector, according to Refinitiv.

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.

One of the major weak points of the company is its financial situation.
The company is not the most generous with respect to shareholders' compensation.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Source: Surperformance

Source: Refinitiv

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	GRIFOLS, S.A.				7.06B
	CSL LIMITED				97.09B
	SAMSUNG BIOLOGICS CO.,LTD.				56.18B
	UCB				33.82B
	BIOGEN INC.				29.34B
	BIOMARIN PHARMACEUTICAL INC.				13.6B
	ALTEOGEN INC.				13.99B
	INCYTE CORPORATION				12.87B
	BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.				12.53B
	SWEDISH ORPHAN BIOVITRUM AB				10.96B
	Average				28.74B
	Weighted average by Cap.